Buy or sell Deep Genomics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Deep Genomics Stock

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.

About Deep Genomics Stock

The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

Funding History

November 2015	$3.7M
September 2017	$13.0M

Management

Co-Founder

Hannes Bretschneider

Research Scientist & Engineer

Alice Gao

Co-Founder

Hui Yuan Xiong

Co-Founder

Andrew Delong

Co-Founder and CEO

Brendan Frey

Press

How Machine Learning Is Crafting Precision Medicine

Forbes - Feb, 11 2019

Khosla Backs AI Startup Creating New Class of Genetic Drugs

Wall Streets Journal - Sep, 25 2017

Other Companies

Learn More

Menten AI

Menten AI utilizes machine learning and quantum computing to design proteins for therapeutic and industrial purposes.

3Age (years)

$4.0MTotal Funding

Learn More

Oxford Nanopore Technologies

Nanopore-Based Electronic Systems

16Age (years)

$0Total Funding

Learn More

Recursion Pharmaceuticals

Automated drug discovery platform

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Deep Genomics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 190K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.